Stayble Therapeutics
Gothenburg, SE · Founded 2015 · 7 employees on LinkedIn · 1 known investors
Stayble Therapeutics is a Swedish biopharmaceutical company that developed STA363, a single-injection, minimally invasive drug candidate to treat pain from lumbar disc herniation by reducing disc volume and relieving nerve pressure. The company completed a Phase 1b study but was declared bankrupt in June 2026, and its IP, patents, and clinical data for STA363 are being offered for sale from the bankruptcy estate.
Investors · 1
Frequently asked questions
- What does Stayble Therapeutics do?
- Stayble Therapeutics is a Swedish biopharmaceutical company that developed STA363, a single-injection, minimally invasive drug candidate to treat pain from lumbar disc herniation by reducing disc volume and relieving nerve pressure. The company completed a Phase 1b study but was declared bankrupt in June 2026, and its IP, patents, and clinical data for STA363 are being offered for sale from the bankruptcy estate.
- Who are Stayble Therapeutics's investors?
- Stayble Therapeutics's investors include Chalmers Ventures AB.
- Where is Stayble Therapeutics headquartered?
- Stayble Therapeutics is headquartered in Gothenburg, SE.